Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Holdings Lowered by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC trimmed its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 35.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 184,155 shares of the specialty pharmaceutical company’s stock after selling 102,500 shares during the period. Bridgeway Capital Management LLC owned about 1.31% of Cumberland Pharmaceuticals worth $436,000 as of its most recent SEC filing.

Cumberland Pharmaceuticals Price Performance

NASDAQ CPIX opened at $4.70 on Monday. The company has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $3.32. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The firm has a market capitalization of $65.65 million, a price-to-earnings ratio of -6.10 and a beta of -0.35. Cumberland Pharmaceuticals Inc. has a 52-week low of $1.04 and a 52-week high of $7.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Analyst Ratings Changes

Separately, StockNews.com raised Cumberland Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday.

Cumberland Pharmaceuticals Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.